Best cytogenetic response to dasatinib
| . | No. patients (%) . | |||
|---|---|---|---|---|
| 6-mo follow-up . | 8-mo follow-up . | |||
| MBC-CML . | LBC-CML . | MBC-CML . | LBC-CML . | |
| No. of patients | 74 | 42 | 74 | 42 |
| Overall cytogenetic response | 31 (42) | 24 (57) | 32 (43) | 24 (57) |
| MCyR | 22 (30) | 21 (50) | 23 (31) | 21 (50) |
| CCyR | 20 (27) | 18 (43) | 20 (27) | 18 (43) |
| PCyR | 2 (3) | 3 (7) | 3 (4) | 3 (7) |
| Minor cytogenetic response | 2 (3) | 0 (0) | 2 (3) | 0 (0) |
| Minimal cytogenetic response | 7 (9) | 3 (7) | 7 (9) | 3 (7) |
| Not evaluable | 19 (26) | 14 (33) | 18 (24) | 14 (33) |
| . | No. patients (%) . | |||
|---|---|---|---|---|
| 6-mo follow-up . | 8-mo follow-up . | |||
| MBC-CML . | LBC-CML . | MBC-CML . | LBC-CML . | |
| No. of patients | 74 | 42 | 74 | 42 |
| Overall cytogenetic response | 31 (42) | 24 (57) | 32 (43) | 24 (57) |
| MCyR | 22 (30) | 21 (50) | 23 (31) | 21 (50) |
| CCyR | 20 (27) | 18 (43) | 20 (27) | 18 (43) |
| PCyR | 2 (3) | 3 (7) | 3 (4) | 3 (7) |
| Minor cytogenetic response | 2 (3) | 0 (0) | 2 (3) | 0 (0) |
| Minimal cytogenetic response | 7 (9) | 3 (7) | 7 (9) | 3 (7) |
| Not evaluable | 19 (26) | 14 (33) | 18 (24) | 14 (33) |
Not evaluable indicates patients who discontinued therapy before the first cytogenetic assessment.